Compare BGLC & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | NXL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Malaysia | United States |
| Employees | N/A | 7 |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.3M |
| IPO Year | 2019 | N/A |
| Metric | BGLC | NXL |
|---|---|---|
| Price | $2.32 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.8K | ★ 114.0K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,510,646.00 | N/A |
| Revenue This Year | N/A | $120.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.36 |
| 52 Week High | $15.19 | $2.31 |
| Indicator | BGLC | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 34.70 |
| Support Level | $2.12 | $0.37 |
| Resistance Level | $2.73 | $0.46 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 34.31 | 7.60 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.